Get started
Author

Marian A. Tiemessen

Observed names: M A Tiemessen, M. Tiemessen, M.A. Tiemessen, Marian A Tiemessen
ORCID: 0000-0003-3046-0510
Observed ORCID: 0000-0003-3046-0510
OpenAlex ID: A5086094913
Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study
2021 · S. Hashemi, M.F. Fransen, et al. · Lung Cancer · 76
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
2020 · Karlijn de Joode, Daphne W. Dumoulin, et al. · European Journal of Cancer · 75
PDF
The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis
2021 · Merle I. Ronden, Idris Bahce, et al. · JTO Clinical and Research Reports · 21
Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer
2021 · on behalf of the eQuiPe study group, Lente L. Kroon, et al. · Journal of Cancer Survivorship · 16
PDF
Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer
2020 · Merle I. Ronden, Idris Bahce, et al. · Lung Cancer · 16
What Goals Do Patients and Oncologists Have When Starting Medical Treatment for Metastatic Lung Cancer?
2020 · Adinda Mieras, H. Roeline W. Pasman, et al. · Clinical Lung Cancer · 15
PDF
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
2021 · Karlijn de Joode, Jolien Tol, et al. · European Journal of Cancer · 9
PDF
Moraxella catarrhalis sepsis in a patient with juvenile spinal muscle atrophy.
2005 · I C D Westendorp, M A Tiemessen, et al. · PubMed · 6
1851MO Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%: Open-label, phase III, randomized trial (PAULIEN)
2025 · I. Houda, E.B. Ulas, et al. · Annals of Oncology · 5
1445P A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
2023 · I. Houda, E.B. Ulas, et al. · Annals of Oncology · 3
PDF
A Massive Calcified Mass in the Lung *
2003 · Marian A. Tiemessen, Peter C. de Bruin, et al. · CHEST Journal · 2
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial
2026 · Ezgi B Ulas, Nora D Purcell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
1020P Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study
2022 · I. Bahce, F.L. Schneiders, et al. · Annals of Oncology · 1
Advance care planning in the last year of life of patients with advanced cancer: patients’ perspectives on decision-making and their family and physicians’ awareness of future care preferences
2026 · Christina A. M. de Laat, Helen P. A. Driessen, et al. · Journal of Cancer Survivorship
PDF
PT2.11.02 Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Metastatic NSCLC Patients: the RECLAIM study
2025 · E.B. Ulas, F.L. Schneiders, et al. · Journal of Thoracic Oncology
P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases
2023 · T. van der Wel, M.C. Boelens, et al. · Journal of Thoracic Oncology
PDF
MA06.06 Treatment Recommendations for Stage III NSCLC by 3 Dutch Multidisciplinary Tumor Boards Prior To, and Following the PACIFIC Trial
2021 · M. Ronden, I. Bahce, et al. · Journal of Thoracic Oncology
PDF
P18.02 Factors Influencing Multi-Disciplinary Tumor Board Recommendations in Stage III Non-Small Cell Lung Cancer
2021 · M. Ronden, I. Bahce, et al. · Journal of Thoracic Oncology
PO-0996: Early mortality in stage III NSCLC after radical non-surgical therapy following ESMO guidelines
2020 · M. Ronden-Kianoush, I.F. Remmerts de Vries, et al. · Radiotherapy and Oncology
PDF
131 Malignant mesothelioma as a second primary malignancy
2006 · S. Burgers, M. Tiemessen, et al. · Lung Cancer
Works count: 21
Citation count: 246
H-index: 7
I10-index: 6
Year
Topic
Type